Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair Compassionate Access in Severe Allergic Asthma
NCT00639691Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2005
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Jan 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00639691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00639691.